Literature DB >> 2502799

Comparative anxiogenic, neuroendocrine, and other physiologic effects of m-chlorophenylpiperazine given intravenously or orally to healthy volunteers.

D L Murphy1, E A Mueller, J L Hill, T J Tolliver, F M Jacobsen.   

Abstract

The serotonin agonist m-chlorophenylpiperazine (m-CPP) had greater anxiogenic and other mood and cognitive effects when administered intravenously (0.1 mg/kg) rather than orally (0.5 mg/kg) to healthy subjects. Nonetheless, similar elevations in peak plasma cortisol and prolactin concentrations were obtained with the two dosage regimens, and temperature elevations were greater after oral m-CPP. Plateau phase plasma concentrations of m-CPP at the times of the maximum neuroendocrine responses to intravenous and oral m-CPP were similar. Since all rodent and nonhuman primate studies have used parenterally administered m-CPP, and previous clinical investigations using intravenous rather than oral m-CPP have yielded somewhat discrepant results, our normative data should be useful for comparing results across different human studies and across species.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2502799     DOI: 10.1007/bf00444705

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  40 in total

1.  5-Hydroxytryptamine-like properties of m-chlorophenylpiperazine: comparison with quipazine.

Authors:  A Rokosz-Pelc; L Antkiewicz-Michaluk; J Vetulani
Journal:  J Pharm Pharmacol       Date:  1980-03       Impact factor: 3.765

2.  Long-term clorgyline treatment antagonizes the eating and motor function responses to m-chlorophenylpiperazine.

Authors:  R M Cohen; C S Aulakh; D L Murphy
Journal:  Eur J Pharmacol       Date:  1983-10-14       Impact factor: 4.432

3.  Serotonin function in anxiety. II. Effects of the serotonin agonist MCPP in panic disorder patients and healthy subjects.

Authors:  D S Charney; S W Woods; W K Goodman; G R Heninger
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530

4.  Further studies of the putative serotonin agonist, m-chlorophenylpiperazine: evidence for a serotonin receptor mediated mechanism of action in humans.

Authors:  E A Mueller; D L Murphy; T Sunderland
Journal:  Psychopharmacology (Berl)       Date:  1986       Impact factor: 4.530

5.  Neuroendocrine effects of M-chlorophenylpiperazine, a serotonin agonist, in humans.

Authors:  E A Mueller; D L Murphy; T Sunderland
Journal:  J Clin Endocrinol Metab       Date:  1985-12       Impact factor: 5.958

6.  Induction of migrainelike headaches by the serotonin agonist m-chlorophenylpiperazine.

Authors:  T D Brewerton; D L Murphy; E A Mueller; D C Jimerson
Journal:  Clin Pharmacol Ther       Date:  1988-06       Impact factor: 6.875

7.  Antagonism of vascular serotonin receptors by m-chlorophenylpiperazine and m-trifluoromethylphenylpiperazine.

Authors:  M L Cohen; R W Fuller
Journal:  Life Sci       Date:  1983-02-14       Impact factor: 5.037

8.  Pharmacological characterization of 5-hydroxytryptamine-induced depolarization of the rat isolated vagus nerve.

Authors:  S J Ireland; M B Tyers
Journal:  Br J Pharmacol       Date:  1987-01       Impact factor: 8.739

9.  Long-term imipramine treatment enhances locomotor and food intake suppressant effects of m-chlorophenylpiperazine in rats.

Authors:  C S Aulakh; R M Cohen; J L Hill; D L Murphy; J Zohar
Journal:  Br J Pharmacol       Date:  1987-08       Impact factor: 8.739

10.  Evidence that mCPP may have behavioural effects mediated by central 5-HT1C receptors.

Authors:  G A Kennett; G Curzon
Journal:  Br J Pharmacol       Date:  1988-05       Impact factor: 8.739

View more
  29 in total

1.  Involvement of 5-HT1B receptors in the anticonflict effect of m-CPP in rats.

Authors:  E Chojnacka-Wójcik; A Kłodzińska
Journal:  J Neural Transm Gen Sect       Date:  1992

2.  5-hydroxytryptamine 2C receptors in the dorsal striatum mediate stress-induced interference with negatively reinforced instrumental escape behavior.

Authors:  P V Strong; J P Christianson; A B Loughridge; J Amat; S F Maier; M Fleshner; B N Greenwood
Journal:  Neuroscience       Date:  2011-09-24       Impact factor: 3.590

3.  Relationship of disinhibition and aggression to blunted prolactin response to meta-chlorophenylpiperazine in cocaine-dependent patients.

Authors:  Ashwin A Patkar; Paolo Mannelli; Kathleen Peindl; Kevin P Hill; Raman Gopalakrishnan; Wade H Berrettini
Journal:  Psychopharmacology (Berl)       Date:  2006-01-17       Impact factor: 4.530

4.  Serotonergic influences on male sexual behavior of rhesus monkeys: effects of serotonin agonists.

Authors:  S M Pomerantz; B C Hepner; J M Wertz
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

Review 5.  The Role of Metabolites of Antidepressants in the Treatment of Depression.

Authors:  M V Rudorfer; W Z Potter
Journal:  CNS Drugs       Date:  1997-04       Impact factor: 5.749

6.  Effects of anxiogenic drugs on the emission of 22- and 50-kHz ultrasonic vocalizations in adult rats.

Authors:  Maria Willadsen; Laura M Best; Markus Wöhr; Paul B S Clarke
Journal:  Psychopharmacology (Berl)       Date:  2018-06-16       Impact factor: 4.530

7.  Mono N-aryl ethylenediamine and piperazine derivatives are GABAA receptor blockers: implications for psychiatry.

Authors:  R F Squires; E Saederup
Journal:  Neurochem Res       Date:  1993-07       Impact factor: 3.996

8.  Experimental studies on 3,4-methylenedioxymethamphetamine (MDA, "ecstasy") and its potential to damage brain serotonin neurons.

Authors:  G A Ricaurte; U D McCann
Journal:  Neurotox Res       Date:  2001-01       Impact factor: 3.911

Review 9.  Choosing appropriate antidepressant therapy in the elderly. A risk-benefit assessment of available agents.

Authors:  A J Flint
Journal:  Drugs Aging       Date:  1998-10       Impact factor: 3.923

10.  Serotonergic modulation of anticholinergic effects on cognition and behavior in elderly humans.

Authors:  J T Little; A Broocks; A Martin; J L Hill; L E Tune; C Mack; M Cantillon; S Molchan; D L Murphy; T Sunderland
Journal:  Psychopharmacology (Berl)       Date:  1995-08       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.